Compare Recursion Pharmaceuticals Inc (RXRX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while TKO Group Holdings Inc trades at $181.62 (market cap $13.06B). The key difference: TKO Group Holdings Inc is far larger — about 5.7× Recursion Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.77% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and TKO Group Holdings Inc for 30 Days on average.
| RXRX | TKO | |
|---|---|---|
Market Cap | $2.31B | $13.06B |
Volume | 40,478,768 | 999,906 |
Sector | Health | Media |
52-Week High | $6.79 | $224.96 |
52-Week Low | $2.84 | $175.58 |
Typical Hold Time | 22 Days | 30 Days |
Enterprise Value | $1.83B | $17.42B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
TKO trades at $178.64, down 1.24% on the day and near a 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings, missing Q2 2026 EPS estimates but beating Q1. Revenue growth is solid, with 2026 guidance raised to $5.3B, though high P/E of 62.68 signals premium valuation. A quarterly dividend of $0.79 was declared for September 2026.
Outlook is supported by strong analyst consensus (89% buy ratings) and a $227 price target, but risks include recent technical weakness, margin pressure, and competitive threats. The stock offers upside if media rights and live event execution drive earnings growth, yet volatility near lows warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
